bioihbjkbjnl/mcl2 huggingface dataset:
Vapocoolant Spray Used Prior to Intravenous (IV) Insertions
Condition: Pain
Intervention: Gebauer Ethyl Chloride; Nature's Tears
Intervention description: Will be administered according to manufacturers recommendations which is to spray the aerosol can for 4-10 seconds from a distance of 3 to 9 inches. Do not spray longer than 10 seconds.; Sterile water mist will be administered 1-2 sprays prior to intravenous access
Intervention MeSH terms: Ethyl Chloride
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Participant)
Enrollment: 30.0
Sex: All
Minimum age: 18 Years
Maximum age: 85 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: Vapocoolant applied prior to IV access

Summary:

      The primary purpose of this study is to determine if by offering a vapocoolant (cold spray)
      to hospital outpatients prior to an intravenous catheter (IV) insertion will increase patient
      satisfaction of IV insertion as well as determine if pain of insertion is decreased.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Any outpatient ordered to undergo a Nuclear Medicine Stress Test and is required to
             have IV access for injection of Radiopharmaceuticals

        Exclusion Criteria:

          -  If it is the first time the patient has had an intravenous catheter inserted

          -  Any patient who is or may be pregnant

          -  Any patient who is breast-feeding

          -  Any patient who has taken a narcotic, sedative and/or anti-anxiety medication within 8
             hours of intervention time.

          -  Any patient who has a known diagnosis of Raynaud's Syndrome or Carpal Tunnel Syndrome.

          -  Any patient who has an allergy or hypersensitivity to Ethyl Chloride.

          -  Any patient under the age of 18 and/or any patient over the age of 85

          -  Any patient who is illiterate

          -  Any patient who is non-English speaking

          -  Any patient with prior experience with a vapocoolant spray.
Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva)
Condition: Plaque Psoriasis
MeSH terms: Psoriasis
Intervention: Calcipotriene/betamethasone
Intervention description: One application to affected areas, once a day for two weeks. The PI may choose to extend treatment until Week 4 if necessary.
Intervention MeSH terms: Betamethasone; Calcipotriene
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 6.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No
Keywords: Localized mild breakthrough

Summary:

      The purpose of this study is to determine if calcipotriene/bethamethasone can safely and
      effectively manage the occurence of LMB (mild localized breakthrough) in patients recieving
      efalizumab (Raptiva) for moderate to severe plaque psoriasis.

      It is hypothesized that calcipotriene/betamethasone (Taclonex) could be used to manage LMB
      and thus allow patients to continue efalizumab without interruption.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Ability to provide written, informed consent and comply with study assessments for the
             full duration of the study.

          -  Age 18 years or older.

          -  Moderate to severe plaque psoriasis being treated with efalizumab.

          -  Develop LMB during efalizumab treatment.

          -  PGA of LMB at least mild (2) excluding face, axillae and groin.

        Exclusion Criteria:

          -  Patients with known hypersensitivity to efalizumab, calcipotriene/betamethasone or any
             of its components.

          -  Pregnant or lactating women.

          -  Known or suspected disorders of calcium metabolism.

          -  Erythrodermic, exfoliative and/or pustular psoriasis.

          -  Concomitant use of topical thaerapy, phototherapy or immunosuppressive agents.

          -  LMB (in areas other than face, axillae or groin) constitutes more than 30% of total
             body surface area.

          -  Patients with generalized inflammatory flare which is defined as widespread worsening
             of psoriasis characterized by erythematous and and edematous lesions within exisiting
             plaques.

          -  Any other condition the investigator believes would pose a significant hazard to the
             subject if the investigational therapy were initiated.
Aspirin and Enoxaparin for VTE in Trauma
Condition: Venous Thromboembolism; Thromboprophylaxis; Trauma
MeSH terms: Thromboembolism; Venous Thromboembolism; Wounds and Injuries
Intervention: Aspirin; Enoxaparin
Intervention description: Daily dose is 81 mg oral tablet; Daily dose is by subcutaneous injection and weight based at the discretion of the treating clinician.
Intervention MeSH terms: Aspirin; Enoxaparin
Phase: Phase 4
Study type: Interventional
Primary purpose: Prevention
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Enrollment: 31.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No
Keywords: Aspirin; Enoxaparin; Thromboprophylaxis; Trauma; Venous thromboembolism

Summary:

      The purpose of this study is to determine if the addition of antiplatelet therapy (i.e.
      aspirin) to low-molecular-weight-heparin (i.e. enoxaparin) will decrease the incidence of
      venous thromboembolism (VTE) in high-risk critically injured patients. The investigators
      further aim to determine the safety and efficacy of dual thromboprophylaxis with aspirin and
      enoxaparin for decreasing the incidence of VTE after trauma.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Age 18 years or older

          -  Blunt or penetrating trauma

          -  Requires VTE thromboprophylaxis

          -  High-risk for VTE

        Exclusion Criteria:

          -  Presence of VTE upon admission

          -  Pregnant or nursing

          -  Inability to give informed consent by patient or healthcare proxy

          -  Contraindication to enoxaparin

          -  Contraindication to aspirin

          -  Epidural or subdural hematoma

          -  Presence, or removal within the last 12 hours, of an epidural or spinal catheter, or
             recent (within the last 12 hours) epidural or spinal anesthesia/procedures
Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia
Condition: Hyperglycemia
MeSH terms: Hyperglycemia
Intervention: NPH insulin plus Complete Insulin Orders; Complete Insulin Orders
Intervention description: NPH dosed per study-specific algorithm which incorporates total daily dosage of steroid to determine NPH dose. Complete insulin orders include background, meal-time and correction factor.; 3-part insulin which includes background, meal-time and correction factor
Intervention MeSH terms: Insulin; Insulin, Globin Zinc; Insulin Glargine; Insulin Lispro; Insulin, Isophane; Isophane Insulin, Human; Isophane insulin, beef
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Enrollment: 72.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No
Keywords: corticosteroid; hyperglycemia; hospital; corticosteroid induced hyperglycemia in the hospital

Summary:

      The objective of this study is to determine the best insulin regimen for hospitalized
      patients who receive high doses of steroids who have high blood glucose.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Men or women aged ≥18 years who receive steroids in doses greater than physiologic
             replacement levels of ≥ 10 mg Prednisone or its equivalent of dexamethasone or
             methylprednisolone.

          -  Have signed the consent form for the study

          -  Have a BG > 180 mg/dL any time during the first 24 hour of steroid administration that
             is above physiological replacement ( ≥ 10 mg Prednisone or equivalent)

          -  Are scheduled to be in hospital ≥ 2 days.

        Exclusion Criteria:

          -  Unable to read or understand English

          -  History of psychiatric disability affecting informed consent or compliance with drug
             intake

          -  Type 1 diabetes

          -  Acute or chronic renal failure (creatinine clearance < 30 mL/min estimated by method
             of Cockcroft and Gault)

          -  Patients in Hospice Care

          -  Age <18 years

          -  Previously enrolled in this study.

          -  Not appropriate for the steroid protocol in judgment of the principal investigator
             and/or attending physician.
Treatment of Diabetes and Depression in Hispanics and African Americans and Its Effect on A1c and Quality of Life.
Condition: Diabetes; Depression
MeSH terms: Diabetes Mellitus; Depression; Depressive Disorder
Intervention: sertraline; Placebo
Intervention description: 50 mg up to 100 mg daily for 6 months; 50 mg up to 100 mg daily for 6 months
Intervention MeSH terms: Sertraline
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Enrollment: 89.0
Sex: All
Minimum age: 21 Years
Healthy volunteers: No
Keywords: Diabetes; Depression; diabetes outcomes; quality of life

Summary:

      This proposed study will test the following hypothesis: Treating depression in Hispanics and
      African Americans with diabetes will improve their HbA1c and quality of life while on
      intervention and six months after intervention.
    

Eligibility criteria:

        Inclusion Criteria:

          -  All patients (men, women) who are African American or Hispanic over the age of 21 who
             have been diagnosed with type 2 diabetes and have a HbA1c of greater than 8.0%.
             Subjects with neuropathic pain will be included in the study. Their pain will be
             assessed via a validated pain scale. Their primary care providers will treat their
             pain as necessary.

        Exclusion Criteria:

          -  Pregnant women, patients on dialysis, patients with liver disease or liver enzymes
             elevated three times above normal, patients with blood pressure greater than 160
             systolic or 95 diastolic on two consecutive visits, patients with history of severe
             depression (as determined by hospitalization or the HAM-D survey) or suicide attempts,
             patients on therapy for depression, patients already taking SSRI's, and patients with
             psychotic features or bipolar disease.
Random-start Ovarian Stimulation in Egg-donors (ROSE)
Condition: Infertility
MeSH terms: Infertility
Intervention: Random start ovarian stimulation; Gonadotrophins; GnRH antagonist; GnRH agonist
Intervention description: Egg-donors will start ovarian stimulation randomly at different moments throughout the menstrual cycle.; Urinary FSH 150-225 IU/d; Cetrorelix acetate 0,25 mg/d starting five days after ovarian stimulation; GnRH agonist triggering with triptorelin 0,2 mg for final follicular maturation.
Intervention MeSH terms: Prolactin Release-Inhibiting Factors
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 15.0
Sex: Female
Minimum age: 18 Years
Maximum age: 35 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: ovarian stimulation; random; egg donation; antagonist; gnrh agonist trigger

Summary:

      The purpose of this prospective single-center study is to evaluate the laboratory outcome
      after random start ovarian stimulation in oocyte donors. The study will be performed in
      egg-donors but this type of treatment has the potential to be implemented in general
      infertility population.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Premenopausal women

          -  18-35 years old

          -  FSH levels < 10 IU/liter

          -  Antral follicle count (AFC) > 10

          -  Regular cycles

          -  Body Mass Index (BMI) < 28

          -  Signed informed consent

        Exclusion Criteria:

          -  Polycystic ovary syndrome (PCOS) patients

          -  Allergy to gonadotrophins

          -  Concomitant participation in other trial
Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Americans With Eyelash Hypotrichosis
Condition: Hypotrichosis
MeSH terms: Hypotrichosis
Intervention: bimatoprost ophthalmic 0.03% solution; vehicle sterile solution (placebo)
Intervention description: Apply one drop of study medication along the upper eyelid margin once daily in the evening; Apply one drop of study medication along the upper eyelid margin once daily in the evening
Intervention MeSH terms: Bimatoprost; Pharmaceutical Solutions
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Enrollment: 89.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      This study will evaluate the safety and efficacy of bimatoprost solution 0.03% once daily to
      the upper eyelid margins (where the eyelashes meet the skin) compared with vehicle in
      increasing overall eyelash prominence in self-identified African American/ethnic black
      subjects exhibiting hypotrichosis of the eyelashes (inadequate or not enough eyelashes).
    

Eligibility criteria:

        Inclusion Criteria:

          -  African American/ethnic black

          -  Adults at least 18 years of age

          -  Eyelash prominence assessment of minimal or moderate

        Exclusion Criteria:

          -  Subjects with uneven lashes or longer on one side than the other

          -  Any eye disease or abnormality

          -  Eye surgery

          -  Severe hyperpigmentation around the eye

          -  Eyelash implants

          -  Eyelash extension application

          -  Any use of eyelash growth products within 6 months

          -  Any use of prescription eyelash growth products

          -  Treatments that may affect hair growth

          -  Requiring eye drop medications for glaucoma
Liposomal Bupivacaine in Total Shoulder Arthroplasty
Condition: Pain
Intervention: Liposomal bupivacaine; Inter-scalene nerve block; Ropivacaine
Intervention description: Local infiltration of liposomal bupivacaine; Pre-operative inter-scalene nerve block; Ropivicaine was used for the inter-scalene nerve block.
Intervention MeSH terms: Bupivacaine; Ropivacaine
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Enrollment: 57.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: Pain control; liposomal bupivacaine; exparel; shoulder arthroplasty

Summary:

      This is a randomized, single blinded, standard of care controlled clinical trial. All adult
      patients over eighteen desiring shoulder arthroplasty will be eligible. The study compares
      pain control and opioid consumption in patients undergoing shoulder arthroplasty between
      patients receiving liposomal bupivacaine and those who underwent a preoperative inter-scalene
      nerve block.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Patients over the age of 18 scheduled for primary shoulder arthroplasty by three
             fellowship trained surgeons will be eligible for inclusion

        Exclusion Criteria:

          -  Patients will be excluded if their medical history presents known allergies or
             intolerance to dexamethasone, opioid or bupivacaine, substantial alcohol or drug
             abuse, and pregnancy.
Antibiotics During Intrauterine Balloon Tamponade Placement
Condition: Obstetric Complication; Postpartum Hemorrhage; Postpartum Endometritis
MeSH terms: Postpartum Hemorrhage; Endometritis; Hemorrhage
Intervention: CeFAZolin 1000 MG; Clindamycin 900 MG in 6 ML Injection
Intervention description: Cefazolin 1000 mg every 8 hours for 3 doses; Clindamycin 900 mg every 8 hours for 3 doses
Intervention MeSH terms: Clindamycin; Clindamycin palmitate; Clindamycin phosphate; Cefazolin
Phase: Phase 4
Study type: Interventional
Primary purpose: Prevention
Allocation: Randomized
Intervention model: Parallel Assignment
Intervention model description: Open label, randomized controlled trial
Masking: None (Open Label)
Enrollment: 11.0
Sex: Female
Minimum age: 18 Years
Healthy volunteers: No
Keywords: Bakri; Intrauterine balloon tamponade; Antibiotics

Summary:

      The goal of this study is to identify whether antibiotics given at the time of placement of
      an intrauterine balloon tamponade (IBT) will result in reduction of the risk of endometritis.
      The investigators hypothesize that antibiotics given at the time of intrauterine balloon
      tamponade will reduce the likelihood of postpartum endometritis.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Female

          -  Able to give consent

          -  Gestational age > 24 weeks

          -  Postpartum

          -  Placement of an IBT within the last 2 hours with plans for it to remain in situ for at
             least 2 hours

          -  Primary obstetrician amenable to proceeding with either method of management during
             the study period.

        Exclusion Criteria:

          -  Age < 18 years old

          -  IBT removed within 2 hours of placement

          -  Chorioamnionitis

          -  Insufficient documentation of demographics, delivery outcomes, or peripartum events
             including postpartum hemorrhage, infectious outcomes
Liposomal Bupivacaine Versus Standard Bupivacaine in the Adductor Canal for Total Knee Arthroplasty
Condition: Pain
Intervention: Peripheral Nerve Blockade; 10 meter walk test on post-operative day 1; In person and over the phone questionnaire; Force transduction of quadriceps strength
Intervention description: Each study arm will receive their respective formulation of local anesthetic, either standard bupivacaine or liposomal bupivacaine upon randomization; Patient asked to walk 10 meters at comfortable pace on post-operative day one when deemed safe to do so by the physical therapist; Presuming the patient has left the hospital each patient will be called on post-operative day 2, 3 to assess nausea, opioid consumption, satisfaction with anesthesia technique, nausea and vomiting as well as pain scores; Patient will be asked to flex quadriceps at maximal ability and a transducer (Kiio device) will record a force value pre operatively and on post operative day 1
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Enrollment: 64.0
Sex: All
Minimum age: 18 Years
Maximum age: 80 Years
Healthy volunteers: No
Keywords: 10 meter walk test; Opioid consumption

Summary:

      Study will evaluate the effect of liposomal bupivacaine versus standard bupivacaine on
      physical therapy measures and pain scores as well as opiate consumption.
    

Eligibility criteria:

        Inclusion Criteria:

          1. The subject is scheduled for elective unilateral TKA;

          2. The subject is ≥ 18 years and ≤ 80 years;

          3. The subject's weight is between 65-130 kg;

          4. The subject's primary anesthesia care team has planned for a neuraxial anesthetic
             (i.e. spinal, epidural or combined-spinal epidural);

          5. The patient agrees to receive an adductor canal block;

          6. American Society of Anesthesiologists class 1-3.

        Exclusion Criteria:

          1. Subject is < 18 years of age or >80 years of age;

          2. Subject is non-English speaking;

          3. Subject is known or believed to be pregnant;

          4. Subject is a prisoner;

          5. Subject has impaired decision-making capacity per discretion of the Investigator;

          6. Symptomatic untreated gastroesophageal reflux or otherwise at risk for perioperative
             aspiration;

          7. Any condition for which the primary anesthesia care team deems neuraxial anesthesia
             inappropriate;

          8. Significant pre-existing neuropathy on the operative limb;

          9. Significant renal, cardiac or hepatic disease per discretion of the investigator;

         10. American Society of Anesthesiologists class 4-5;

         11. Known hypersensitivity and/or allergies to local anesthetics;

         12. Chronic Opioid Use (daily or almost daily use of opioids for > 3 months).
Effect of CES on Parasympathetic Tone
Condition: Autonomic Nervous System Imbalance
Intervention: Cranial Electrical Stimulation Fisher-Wallace Stimulator (Model FW100)
Intervention description: low voltage alternating current transcranial electrical stimulation
Phase: Phase 4
Study type: Interventional
Primary purpose: Basic Science
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Double (Participant, Outcomes Assessor)
Masking description: Individual calculating heart rate and heart rate variability from ECG recordings was blind to dose of stimulation. Individual collecting side effect information was not blind to dose of stimulation.
Enrollment: 21.0
Sex: All
Minimum age: 18 Years
Maximum age: 65 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: cranial electrical stimulation; CES; heart rate variability; parasympathetic; Vagal

Summary:

      The hypothesis is that CES stimulation will dose dependently increase parasympathetic tone.
      Healthy subjects will have three 20 minute sessions of CES stimulation, at three different
      intensities of stimulation, with each session occurring on a separate day. Effect on
      parasympathetic tone will determined by measuring high frequency heart rate variability
      before, during and after the stimulation. The Fisher Wallace Stimulator (FW100) which
      delivers a low dose alternating current a varying frequencies will be used for the
      stimulation.
    

Eligibility criteria:

        Inclusion Criteria:

          -  healthy volunteer

        Exclusion Criteria:

          -  daily psychotropic medication,

          -  use of beta blocker,

          -  pacemaker,

          -  other metal in body,

          -  history of seizures